216 related articles for article (PubMed ID: 29279357)
1. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.
Fox TA; Chakraverty R; Burns S; Carpenter B; Thomson K; Lowe D; Fielding A; Peggs K; Kottaridis P; Uttenthal B; Bigley V; Buckland M; Grandage V; Denovan S; Grace S; Dahlstrom J; Workman S; Symes A; Mackinnon S; Hough R; Morris E
Blood; 2018 Feb; 131(8):917-931. PubMed ID: 29279357
[TBL] [Abstract][Full Text] [Related]
2. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
3. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Slatter MA; Rao K; Abd Hamid IJ; Nademi Z; Chiesa R; Elfeky R; Pearce MS; Amrolia P; Worth A; Flood T; Abinun M; Hambleton S; Qasim W; Gaspar HB; Cant AJ; Gennery AR; Veys P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):529-536. PubMed ID: 29155317
[TBL] [Abstract][Full Text] [Related]
4. Post-Transplant CD34
Chandra S; Bleesing JJ; Jordan MB; Grimley MS; Khandelwal P; Davies SM; Edwards S; Leemhuis T; Marsh RA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1527-1529. PubMed ID: 29555312
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.
Hamidieh AA; Behfar M; Pourpak Z; Faghihi-Kashani S; Fazlollahi MR; Hosseini AS; Movahedi M; Mozafari M; Moin M; Ghavamzadeh A
Bone Marrow Transplant; 2016 Feb; 51(2):219-26. PubMed ID: 26595073
[TBL] [Abstract][Full Text] [Related]
6. Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen.
Rao K; Adams S; Qasim W; Allwood Z; Worth A; Silva J; Lucchini G; Chiesa R; Veys P; Amrolia P
J Allergy Clin Immunol; 2016 Oct; 138(4):1152-1160. PubMed ID: 27241891
[TBL] [Abstract][Full Text] [Related]
7. T-cell receptor αβ
Shah RM; Elfeky R; Nademi Z; Qasim W; Amrolia P; Chiesa R; Rao K; Lucchini G; Silva JMF; Worth A; Barge D; Ryan D; Conn J; Cant AJ; Skinner R; Abd Hamid IJ; Flood T; Abinun M; Hambleton S; Gennery AR; Veys P; Slatter M
J Allergy Clin Immunol; 2018 Apr; 141(4):1417-1426.e1. PubMed ID: 28780238
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.
Chewning JH; Castro-Malaspina H; Jakubowski A; Kernan NA; Papadopoulos EB; Small TN; Heller G; Hsu KC; Perales MA; van den Brink MR; Young JW; Prockop SE; Collins NH; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1313-23. PubMed ID: 17950918
[TBL] [Abstract][Full Text] [Related]
9. Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency.
Marçais A; Mahlaoui N; Neven B; Lanternier F; Catherinot É; Salvator H; Cheminant M; Jeljeli M; Asnafi V; van Endert P; Couderc LJ; Lortholary O; Picard C; Moshous D; Hermine O; Fischer A; Suarez F
Bone Marrow Transplant; 2022 Oct; 57(10):1520-1530. PubMed ID: 35794259
[TBL] [Abstract][Full Text] [Related]
10. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
Chen X; Wei JL; Huang Y; He Y; Yang DL; Jiang EL; Ma QL; Zhou LK; Lin XT; Shen YY; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):610-4. PubMed ID: 23134851
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
Nishimura A; Aoki Y; Ishiwata Y; Ichimura T; Ueyama J; Kawahara Y; Tomoda T; Inoue M; Matsumoto K; Inoue K; Hiroki H; Ono S; Yamashita M; Okano T; Tanaka-Kubota M; Ashiarai M; Miyamoto S; Miyawaki R; Yamagishi C; Tezuka M; Okawa T; Hoshino A; Endo A; Yasuhara M; Kamiya T; Mitsuiki N; Ono T; Isoda T; Yanagimachi M; Tomizawa D; Nagasawa M; Mizutani S; Kajiwara M; Takagi M; Kanegane H; Imai K; Morio T
J Clin Immunol; 2021 Jul; 41(5):944-957. PubMed ID: 33527309
[TBL] [Abstract][Full Text] [Related]
12. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
[TBL] [Abstract][Full Text] [Related]
13. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.
Khandelwal P; Bleesing JJ; Davies SM; Marsh RA
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2011-2018. PubMed ID: 27543157
[TBL] [Abstract][Full Text] [Related]
14. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
16. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan.
Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Ghafoor T; Shamshad GU; Farhan M; Shahbaz N; Khan MA; Khattak TA; Rehman J; Humayun S; Satti HS; Anwer F; Ahmed P
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2375-2382. PubMed ID: 31394274
[TBL] [Abstract][Full Text] [Related]
18. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiencies in Korea: Eleven-Year Experience in a Single Center.
Yi ES; Choi YB; Lee NH; Lee JW; Sung KW; Koo HH; Kang ES; Kim YJ; Yoo KH
J Clin Immunol; 2018 Oct; 38(7):757-766. PubMed ID: 30151618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
